119 related articles for article (PubMed ID: 11705884)
1. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
2. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
Zhang Z; Li M; Wang H; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
[TBL] [Abstract][Full Text] [Related]
3. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
Pairawan S; Zhao M; Yuca E; Annis A; Evans K; Sutton D; Carvajal L; Ren JG; Santiago S; Guerlavais V; Akcakanat A; Tapia C; Yang F; Bose PSC; Zheng X; Dumbrava EI; Aivado M; Meric-Bernstam F
Breast Cancer Res; 2021 Mar; 23(1):29. PubMed ID: 33663585
[TBL] [Abstract][Full Text] [Related]
4. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract][Full Text] [Related]
5. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.
Yi H; Yan X; Luo Q; Yuan L; Li B; Pan W; Zhang L; Chen H; Wang J; Zhang Y; Zhai Y; Qiu MZ; Yang DJ
J Exp Clin Cancer Res; 2018 May; 37(1):97. PubMed ID: 29716622
[TBL] [Abstract][Full Text] [Related]
6. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.
Wang W; Qin JJ; Voruganti S; Srivenugopal KS; Nag S; Patil S; Sharma H; Wang MH; Wang H; Buolamwini JK; Zhang R
Nat Commun; 2014 Oct; 5():5086. PubMed ID: 25271708
[TBL] [Abstract][Full Text] [Related]
7. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract][Full Text] [Related]
8. Improving anticancer activity towards colon cancer cells with a new p53-activating agent.
Raimundo L; Espadinha M; Soares J; Loureiro JB; Alves MG; Santos MMM; Saraiva L
Br J Pharmacol; 2018 Oct; 175(20):3947-3962. PubMed ID: 30076608
[TBL] [Abstract][Full Text] [Related]
9. Prion protein-dependent regulation of p53-MDM2 crosstalk during endoplasmic reticulum stress and doxorubicin treatments might be essential for cell fate in human breast cancer cell line, MCF-7.
Tuğrul B; Balcan E; Öztel Z; Çöllü F; Gürcü B
Exp Cell Res; 2023 Aug; 429(1):113656. PubMed ID: 37245583
[TBL] [Abstract][Full Text] [Related]
10. LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development.
Zhou L; Tian Y; Guo F; Yu B; Li J; Xu H; Su Z
Cancer Immunol Immunother; 2020 May; 69(5):835-846. PubMed ID: 32062693
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.
Chessari G; Hardcastle IR; Ahn JS; Anil B; Anscombe E; Bawn RH; Bevan LD; Blackburn TJ; Buck I; Cano C; Carbain B; Castro J; Cons B; Cully SJ; Endicott JA; Fazal L; Golding BT; Griffin RJ; Haggerty K; Harnor SJ; Hearn K; Hobson S; Holvey RS; Howard S; Jennings CE; Johnson CN; Lunec J; Miller DC; Newell DR; Noble MEM; Reeks J; Revill CH; Riedinger C; St Denis JD; Tamanini E; Thomas H; Thompson NT; Vinković M; Wedge SR; Williams PA; Wilsher NE; Zhang B; Zhao Y
J Med Chem; 2021 Apr; 64(7):4071-4088. PubMed ID: 33761253
[TBL] [Abstract][Full Text] [Related]
12. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
Golubovskaya VM; Ho B; Zheng M; Magis A; Ostrov D; Morrison C; Cance WG
BMC Cancer; 2013 Jul; 13():342. PubMed ID: 23841915
[TBL] [Abstract][Full Text] [Related]
13. Death-associated protein kinase 1 phosphorylates MDM2 and inhibits its protein stability and function.
Zhang M; Shui X; Zheng X; Lee JE; Mei Y; Li R; Tian Y; Zheng X; Wang Q; Wang L; Chen D; Zhang T; Kim BM; Kim J; Lee TH
Arch Pharm Res; 2023 Dec; 46(11-12):882-896. PubMed ID: 37804415
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53.
Liu Z; Yang Y; Sun X; Ma R; Zhang W; Wang W; Yang G; Wang H; Zhang J; Wang Y; Tian J
Molecules; 2024 Feb; 29(3):. PubMed ID: 38338471
[TBL] [Abstract][Full Text] [Related]
15. ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2.
Ma X; Fan M; Yang K; Wang Y; Hu R; Guan M; Hou Y; Ying J; Deng N; Li Q; Jiang G; Zhang Y; Zhang X
Cancer Sci; 2023 Nov; 114(11):4237-4251. PubMed ID: 37700392
[TBL] [Abstract][Full Text] [Related]
16. Sodium cantharidate induces Apoptosis in breast cancer cells by regulating energy metabolism via the protein phosphatase 5-p53 axis.
Pang JL; Huang FH; Zhang YH; Wu Y; Ge XM; Li S; Li X
Toxicol Appl Pharmacol; 2021 Nov; 430():115726. PubMed ID: 34537213
[TBL] [Abstract][Full Text] [Related]
17. MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production.
Langenbach M; Giesler S; Richtsfeld S; Costa-Pereira S; Rindlisbacher L; Wertheimer T; Braun LM; Andrieux G; Duquesne S; Pfeifer D; Woessner NM; Menssen HD; Taromi S; Duyster J; Börries M; Brummer T; Blazar BR; Minguet S; Turko P; Levesque MP; Becher B; Zeiser R
Mol Cancer Res; 2023 Aug; 21(8):849-864. PubMed ID: 37071397
[TBL] [Abstract][Full Text] [Related]
18. Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism.
Ruhnau J; Parczyk J; Danker K; Eickholt B; Klein A
BMC Cancer; 2020 Jul; 20(1):617. PubMed ID: 32615946
[TBL] [Abstract][Full Text] [Related]
19. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts.
Huang F; Mazin AV
PLoS One; 2014; 9(6):e100993. PubMed ID: 24971740
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine derivatives as MDM2 inhibitors.
Mehri A; Mahnam K; Sirous H; Aghaei M; Rafiei L; Rostami M
Chem Biol Drug Des; 2024 Jan; 103(1):e14399. PubMed ID: 38011915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]